In my opinion; the next round of financing should only a final (and decisive) decision by BD or perhaps Lilly (or another interested party) on LymPro. I feel good and somewhat confident once the results are validated by BD (either they or another interested Pharma. will look to potentially partner).
Most reasonable, most likely possibilites for financing as the MANF RP Orphan PR is from an abstract over a year old without any subsequent published comment from the Ophthalmic community, or from AMBS for that matter.